Riccardo Braglia, Helsinn

Helsinn, the Braglia fam­i­ly phar­ma, sees some big changes in lead­er­ship as it un­veils a new R&D strat­e­gy

For any­one who’s been pay­ing close at­ten­tion, Helsinn’s shift to tar­get­ed can­cer ther­a­pies has been a long time com­ing. But on Thurs­day, the com­pa­ny of­fi­cial­ly un­veiled its new strat­e­gy — and with it, some big struc­tur­al and lead­er­ship changes.

Helsinn is stray­ing away from its suc­cess as a can­cer sup­port­ive care com­pa­ny and turn­ing to a new so-called Ful­ly In­te­grat­ed Tar­get­ed Ther­a­py (FITT) strat­e­gy, the Braglia fam­i­ly an­nounced Thurs­day. Gior­gio Calder­ari, who’s been with the com­pa­ny for the last 36 years, has been tapped to lead the charge as CEO, while Ric­car­do Braglia steps in­to his dad’s old role as ex­ec­u­tive chair­man.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.